Spero Therapeutics, Inc. SPRO Balance Sheet

Spero therapeutics, inc. (SPRO)

Balance Sheet / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Dec'16
Assets
Current assets:
Cash and cash equivalents
64,363	29,730	45,597	71,133	49,395	34,080	40,480	48,715	52,552	87,288	25,373	10,315
Marketable securities
24,478	52,315	48,259	32,275	56,997	81,363	90,745	17,922	22,841	-	-	-
Other receivables
2,724	7,760	5,013	2,073	456	376	332	794	1,219	1,011	537	304
Tax incentive receivable, current
712	786	1,425	921	928	922	944	1,830	1,902	1,932	-	-
Prepaid expenses and other current assets
5,683	4,823	3,676	6,288	7,926	7,478	1,222	1,231	1,224	1,828	1,049	1,253
Total current assets
97,960	95,414	103,970	112,690	115,702	124,219	133,723	70,492	79,738	92,059	26,959	11,872
Property and equipment, net
2,163	2,273	2,519	2,689	2,864	2,893	2,191	975	1,070	1,164	1,264	1,500
Tax incentive receivable
262	21	-	474	294	233	-	426	45	-	976	144
Operating lease right of use assets
4,765	4,875	3,944	4,187	4,369	-	-	-	-	-	-	-
Deposits
-	-	-	-	-	-	206	206	206	206	206	206
Deferred offering costs
-	-	-	-	-	-	-	493	-	-	2,095	-
Other assets
4,744	3,520	2,077	2,449	1,421	1,661	-	-	-	-	-	-
Restricted cash
-	-	-	-	-	-	-	-	-	50	50	50
Total assets
109,894	106,103	112,510	122,489	124,650	129,006	136,120	72,592	81,059	93,479	31,550	13,772
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable
8,951	4,147	2,524	1,039	557	3,603	1,364	705	982	3,470	2,011	1,139
Accrued expenses and other current liabilities
12,858	21,588	11,869	6,416	5,199	8,263	8,564	5,547	4,484	4,321	4,504	2,928
Derivative liabilities
-	-	223	223	223	223	223	223	223	223	217	2,708
Deferred rent
-	-	-	-	-	229	127	126	145	143	142	143
Operating lease liabilities
932	928	442	571	639	-	-	-	-	-	-	-
Total current liabilities
22,741	26,663	15,058	8,249	6,618	12,318	10,278	6,601	5,834	8,157	6,874	6,918
Deferred rent, net of current portion
-	-	-	-	-	833	290	323	327	365	399	493
Non-current operating lease liabilities
4,521	4,617	4,162	4,278	4,391	-	-	-	-	-	-	-
Other long-term liabilities
205	249	256	293	312	-	-	-	-	-	-	-
Total liabilities
27,467	31,529	19,476	12,820	11,321	13,151	10,568	6,924	6,161	8,522	7,273	7,411
Commitments and contingencies (Note 9)
-	-	-	-	-	-	0	0	0	-	0	0
Stockholders' equity:
Common units, zero and 335,281 units issued and outstanding as of December 31, 2017 and 2016, respectively
-	-	-	-	-	-	-	-	-	-	-	0
Preferred stock, $0.001 par value; 10,000,000 shares authorized, 5,007 shares issued and outstanding as of March 31, 2020 and 2,720 shares issued and outstanding as of December 31, 2019
-	-	-	-	-	-	0	0	0	-	-	0
Common stock, $0.001 par value; 60,000,000 shares authorized as of March 31, 2020 and December 31, 2019; 20,328,340 shares issued and outstanding as of March 31, 2020 and 19,190,695 shares issued and outstanding as of December 31, 2019
20	19	19	19	17	17	18	14	14	14	0	-
Additional paid-in capital
305,111	273,966	-	-	-	254,013	-	-	-	-	-	-
Additional paid-in capital
-	-	267,083	266,013	256,530	-	253,105	182,754	182,042	181,428	0	-
Accumulated deficit
-222,685	-199,427	-174,441	-156,724	-143,574	-138,502	-127,903	-117,440	-107,484	-96,840	-82,194	-45,440
Accumulated other comprehensive gain (loss)
-19	16	18	6	1	-28	-23	-15	-29	-	-	-
Total stockholders' equity
82,427	74,574	92,679	109,314	112,974	115,500	125,197	65,313	74,543	84,602	-82,194	-45,440
Non-controlling interests
-	-	355	355	355	355	355	355	355	355	361	-3,808
Total stockholders' equity
-	-	93,034	109,669	113,329	115,855	125,552	65,668	74,898	84,957	-81,833	-49,248
Total liabilities and stockholders' equity
109,894	106,103	112,510	122,489	124,650	129,006	136,120	72,592	81,059	93,479	31,550	13,772